AstraZeneca offers some detail on China probe, reaffirms commitment to that market

Ayisha Sharma

News Reporter

LONDON — AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, giving investors and analysts some reassurance …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Pfizer hires Novartis oncology exec to steer its cancer ambitions

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

AstraZeneca offers some detail on China probe, reaffirms commitment to that market